利用肿瘤浸润淋巴细胞预测化疗（帕妥珠单抗、曲妥珠单抗、多西他赛）对HER2阳性乳腺癌的治疗效果。
Using TILs to Predict Therapeutic Effect of Chemotherapy (Pertuzumab, Trastuzumab, Docetaxel) on HER2-positive Breast Cancer.
作者信息
Kashiwagi Shinichiro, Asano Yuka, Goto Wataru, Takada Koji, Takahashi Katsuyuki, Hatano Takaharu, Takashima Tsutomu, Tomita Shuhei, Motomura Hisashi, Ohsawa Masahiko, Hirakawa Kosei, Ohira Masaichi
机构信息
Department of Surgical Oncology, Osaka City University Graduate School of Medicine, Osaka, Japan
Department of Surgical Oncology, Osaka City University Graduate School of Medicine, Osaka, Japan.
出版信息
Anticancer Res. 2017 Oct;37(10):5623-5630. doi: 10.21873/anticanres.11997.
BACKGROUND/AIM: Recently, reports of the clinical implications of tumor-infiltrating lymphocytes (TILs) in breast cancer treatment have increased. We evaluated that chemotherapy with a TPD regimen (trastuzumab, pertuzumab, docetaxel) against HER2-positive breast cancer, using TILs as indicators.
PATIENTS AND METHODS
The subjects were 24 patients who had received TPD-chemotherapy. A semi-quantitative evaluation of lymphocytes invading the stroma in needle biopsy specimens prior to treatment as TILs was conducted, after which, sensitivity to chemotherapy and patient prognosis were evaluated.
RESULTS
Overall response rate was significantly higher in the high-TILs group than in the low-TILs group. Significant extension of the progression-free survival (PFS) and overall survival was found in the high-TILs group compared to the low-TILs group. In addition, high TILs numbers significantly contributed to the extension of PFS.
CONCLUSION
Monitoring antitumor immune response using TILs might be a useful indicator for predicting the curative effects of TPD chemotherapy for HER2-positive breast cancer.
背景/目的：最近，关于肿瘤浸润淋巴细胞（TILs）在乳腺癌治疗中的临床意义的报道有所增加。我们以TILs为指标，评估了TPD方案（曲妥珠单抗、帕妥珠单抗、多西他赛）化疗对HER2阳性乳腺癌的疗效。
患者与方法
研究对象为24例接受TPD化疗的患者。在治疗前，对穿刺活检标本中浸润基质的淋巴细胞进行半定量评估作为TILs，之后评估化疗敏感性和患者预后。
结果
高TILs组的总缓解率显著高于低TILs组。与低TILs组相比，高TILs组的无进展生存期（PFS）和总生存期显著延长。此外，高TILs数量对PFS的延长有显著贡献。
结论
使用TILs监测抗肿瘤免疫反应可能是预测TPD化疗对HER2阳性乳腺癌疗效的有用指标。
Zotero 插件